A new model that combines real-world prices with outcome data from both controlled trials and clinical practice indicates that the immediate use of tumor necrosis factor inhibitors (anti-TNFs) is a cost-effective way to achieve good first-year outcomes in patients newly diagnosed with both plaque psoriasis and psoriatic arthritis.
The authors say that for uveitis “there is a large unmet medical need" for identifying other therapies. Adalimumab is associated with deceased visual impairment and decreased risk of uveitic flare, but more adverse events, according the results from a recent multinational phase 3 trial.
Ixekizumab patients, who all started with an introductory 160-mg dose, were all more likely than placebo patients to achieve the primary endpoint of the study: a 20% reduction in disease burden as measured by American College of Rheumatology criteria (an ACR20 response) by week 24.
As newer treatment options hit the market for plaque psoriasis patients may have more questions about the best options for them. This is part of the importance of communicating with patients throughout the treatment process.
As with many conditions, the kind of care a patient receives can depend on where they live. This can be especially true for dermatology patients needing things like phototherapy. Other factors, like cost and fear, can also impede the treatment process.